Cutaneous T-Cell Lymphoma News

Expert Shares Insight on Developments in T-Cell Lymphoma - OncLive



OncLive
 
Expert Shares Insight on Developments in T-Cell Lymphoma 
OncLive
At the 2017 ASH Annual Meeting, researchers presented an abstract looking at pembrolizumab (Keytruda) in patients with cutaneous T-cell lymphoma who had relapsed disease. Some of these patients had relapsed 4 to 6 times with cutaneous T-cell ...

 


miRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG ... - GlobeNewswire (press release)



miRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG ... 
GlobeNewswire (press release)
miRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at EORTC Global Task Force Meeting ...
Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in ... PR Newswire (press release)
miRagen Therapeutics presents new clinical data from MRG-106 on mycosis fungoides; shares ahead 11% premarket Seeking Alpha

all 4 news articles » 


Cutaneous T-Cell Lymphoma epidemiology 2017 - Medgadget (blog)



Cutaneous T-Cell Lymphoma epidemiology 2017 
Medgadget (blog)
Cutaneous T-Cell Lymphoma- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the ...

and more » 


Trillium Therapeutics' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference - Marketwired (press release)



Trillium Therapeutics' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference 
Marketwired (press release)
This oral presentation highlighted that leukemic cells from patients with SÚzary syndrome, a form of cutaneous T cell lymphoma (CTCL), express the CD47 "do not eat" signal at almost four times the level of normal lymphocytes and that over-expression of ...

and more » 


Cutaneous T-Cell Lymphoma Market Research Report 2017 to 2025 - E News Access (press release)



Cutaneous T-Cell Lymphoma Market Research Report 2017 to 2025 
E News Access (press release)
Cutaneous T-Cell Lymphoma- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the ...

and more » 


20s Proteasome - Pipeline Review, H2 2017 - PR Newswire (press release)



20s Proteasome - Pipeline Review, H2 2017 
PR Newswire (press release)
... Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Endometriosis, Glioblastoma Multiforme (GBM), Gliosarcoma, Hematological Tumor, Kidney Transplant Rejection, Lymphoma, Malignant Glioma, Mantle Cell Lymphoma, Metastatic Hormone ...

and more » 


INNATE PHARMA : IPH4102: Final results of the dose-escalation part of the Phase I study - GlobeNewswire (press release)



INNATE PHARMA : IPH4102: Final results of the dose-escalation part of the Phase I study 
GlobeNewswire (press release)
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) announces that final results of the dose-escalation part of the ongoing Phase I study investigating IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas (CTCL), ...

and more » 


Clinical Trial Evaluating Resminostat as Maintenance Therapy in CTCL Is Enrolling Participants - Lymphoma News Today



Lymphoma News Today
 
Clinical Trial Evaluating Resminostat as Maintenance Therapy in CTCL Is Enrolling Participants 
Lymphoma News Today
A Phase 2 trial is currently enrolling participants to evaluate 4SC's investigational therapy resminostat as a maintenance therapy for advanced-stage cutaneous T-cell lymphoma (CTCL). The RESMAIN study (NCT02953301) is being conducted at about 50 ...

 


German Biotech Uses Epigenetics to Tackle Aggravating Side Effect in Cancer Patients - Labiotech.eu (blog)



Labiotech.eu (blog)
 
German Biotech Uses Epigenetics to Tackle Aggravating Side Effect in Cancer Patients 
Labiotech.eu (blog)
Severe itching is a major burden for people living with cutaneous T-cell lymphoma, but 4SC's candidate can effectively reduce the sensation. 4SC is developing resminostat as a maintenance therapy for patients with cutaneous T-cell lymphoma (CTCL).

 


Financial Survey: Tetralogic Pharmaceuticals Corp (TLOG) and Its Peers - TrueBlueTribune



Financial Survey: Tetralogic Pharmaceuticals Corp (TLOG) and Its Peers 
TrueBlueTribune
SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin ...